Rhian M Touyz

List of Publications by Year
in descending order

654	78,577	764 119	621 258
papers	citations	h-index	g-index

696	696	696	61580
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
3	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871
4	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
5	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	1.0	3,048
6	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
7	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
8	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
9	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 2020, 116, 1666-1687.	1.8	1,074
10	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	1.0	971
11	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research, 2020, 126, 1671-1681.	2.0	948
12	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology, 2018, 34, 575-584.	0.8	945
13	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
14	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Clinical Hypertension, 2014, 16, 14-26.	1.0	768
15	Reactive Oxygen Species, Vascular Oxidative Stress, and Redox Signaling in Hypertension. Hypertension, 2004, 44, 248-252.	1.3	763
16	Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacological Reviews, 2000, 52, 639-72.	7.1	672
17	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	1.0	647
18	NADPH Oxidases, Reactive Oxygen Species, and Hypertension. Diabetes Care, 2008, 31, S170-S180.	4.3	608

#	Article	IF	Citations
19	Correction of Arterial Structure and Endothelial Dysfunction in Human Essential Hypertension by the Angiotensin Receptor Antagonist Losartan. Circulation, 2000, 101, 1653-1659.	1.6	584
20	Expression of a Functionally Active gp91phox-Containing Neutrophil-Type NAD(P)H Oxidase in Smooth Muscle Cells From Human Resistance Arteries. Circulation Research, 2002, 90, 1205-1213.	2.0	558
21	Reactive oxygen species in vascular biology: implications in hypertension. Histochemistry and Cell Biology, 2004, 122, 339-352.	0.8	553
22	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Hypertension, 2014, 32, 3-15.	0.3	498
23	Redox signaling in hypertension. Cardiovascular Research, 2006, 71, 247-258.	1.8	477
24	Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways. Hypertension, 2007, 49, 185-192.	1.3	470
25	Vascular dysfunctionâ€"The disregarded partner of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 158-167.	0.4	454
26	Oxidative Stress, Inflammation, and Vascular Aging in Hypertension. Hypertension, 2017, 70, 660-667.	1.3	453
27	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. Journal of the American College of Cardiology, 2018, 72, 2841-2855.	1.2	436
28	Vascular smooth muscle contraction in hypertension. Cardiovascular Research, 2018, 114, 529-539.	1.8	393
29	Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress. Hypertension, 2002, 40, 504-510.	1.3	373
30	Reactive oxygen species and vascular biology: implications in human hypertension. Hypertension Research, 2011, 34, 5-14.	1.5	371
31	NADPH Oxidases, Reactive Oxygen Species, and the Kidney. Journal of the American Society of Nephrology: JASN, 2013, 24, 1512-1518.	3.0	361
32	Angiotensin II, NADPH Oxidase, and Redox Signaling in the Vasculature. Antioxidants and Redox Signaling, 2013, 19, 1110-1120.	2.5	350
33	Antioxidant Effects of Vitamins C and E Are Associated With Altered Activation of Vascular NADPH Oxidase and Superoxide Dismutase in Stroke-Prone SHR. Hypertension, 2001, 38, 606-611.	1.3	345
34	Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2010, 299, F1348-F1358.	1.3	329
35	NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitusâ€"Accelerated Atherosclerosis. Circulation, 2013, 127, 1888-1902.	1.6	325
36	Angiotensin II and Vascular Injury. Current Hypertension Reports, 2014, 16, 431.	1.5	308

#	Article	IF	Citations
37	The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovascular Research, 2017, 113, 1009-1023.	1.8	302
38	Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1237-1254.	3.0	301
39	Microparticles: biomarkers and beyond. Clinical Science, 2013, 124, 423-441.	1.8	299
40	Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. Canadian Journal of Cardiology, 2016, 32, 659-668.	0.8	298
41	Endothelium-Restricted Overexpression of Human Endothelin-1 Causes Vascular Remodeling and Endothelial Dysfunction. Circulation, 2004, 110, 2233-2240.	1.6	296
42	Reduced Vascular Remodeling, Endothelial Dysfunction, and Oxidative Stress in Resistance Arteries of Angiotensin IIâ€“Infused Macrophage Colony-Stimulating Factorâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2106-2113.	1.1	293
43	Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways. Hypertension, 2012, 59, 1069-1078.	1.3	292
44	Measurement of Reactive Oxygen Species, Reactive Nitrogen Species, and Redox-Dependent Signaling in the Cardiovascular System. Circulation Research, 2016, 119, e39-75.	2.0	290
45	Oxidative Stress and Hypertension: Current Concepts. Current Hypertension Reports, 2010, 12, 135-142.	1.5	288
46	Reactive oxygen species and angiotensin II signaling in vascular cells: implications in cardiovascular disease. Brazilian Journal of Medical and Biological Research, 2004, 37, 1263-1273.	0.7	272
47	Oxidative Stress and Human Hypertension: Vascular Mechanisms, Biomarkers, and Novel Therapies. Canadian Journal of Cardiology, 2015, 31, 631-641.	0.8	257
48	c-Src Induces Phosphorylation and Translocation of p47phox. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 981-987.	1.1	254
49	Reactive Oxygen Species and Endothelial Function â€“ Role of Nitric Oxide Synthase Uncoupling and Nox Family Nicotinamide Adenine Dinucleotide Phosphate Oxidases. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 87-94.	1.2	242
50	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	3.9	242
51	A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme. Pharmacological Reviews, 2013, 65, 1-46.	7.1	240
52	Angiotensin-(1-7) Counterregulates Angiotensin II Signaling in Human Endothelial Cells. Hypertension, 2007, 50, 1093-1098.	1.3	239
53	Vascular biology of ageingâ€”Implications in hypertension. Journal of Molecular and Cellular Cardiology, 2015, 83, 112-121.	0.9	237
54	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacological Reviews, 2019, 71, 539-570.	7.1	235

#	Article	IF	Citations
55	Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. Journal of Hypertension, 2001, 19, 1245-1254.	0.3	234
56	Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling. Hypertension, 2003, 42, 49-55.	1.3	227
57	Reactive Oxygen Species, Vascular Noxs, and Hypertension: Focus on Translational and Clinical Research. Antioxidants and Redox Signaling, 2014, 20, 164-182.	2.5	222
58	PPARÎ± Activator Effects on Ang Iiâ€“Induced Vascular Oxidative Stress and Inflammation. Hypertension, 2002, 40, 866-871.	1.3	221
59	From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H435-H446.	1.5	220
60	Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-Src. Hypertension, 2005, 45, 773-779.	1.3	220
61	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
62	Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. Journal of Hypertension, 2004, 22, 535-542.	0.3	218
63	Oxidases and peroxidases in cardiovascular and lung disease: New concepts in reactive oxygen species signaling. Free Radical Biology and Medicine, 2011, 51, 1271-1288.	1.3	218
64	Angiotensin(1-7) Blunts Hypertensive Cardiac Remodeling by a Direct Effect on the Heart. Circulation Research, 2008, 103, 1319-1326.	2.0	206
65	Recent advances in angiotensin II signaling. Brazilian Journal of Medical and Biological Research, 2002, 35, 1001-1015.	0.7	205
66	Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Experimental Physiology, 2005, 90, 449-455.	0.9	199
67	Molecular Mechanisms of Hypertensionâ€”Reactive Oxygen Species and Antioxidants: A Basic Science Update for the Clinician. Canadian Journal of Cardiology, 2012, 28, 288-295.	0.8	199
68	Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 860-866.	0.9	195
69	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	1.0	193
70	Ang Iiâ€“Stimulated Superoxide Production Is Mediated via Phospholipase D in Human Vascular Smooth Muscle Cells. Hypertension, 1999, 34, 976-982.	1.3	192
71	Reactive Oxygen Species as Mediators of Calcium Signaling by Angiotensin II: Implications in Vascular Physiology and Pathophysiology. Antioxidants and Redox Signaling, 2005, 7, 1302-1314.	2.5	192
72	Vascular Smooth Muscle Cell Differentiation to an Osteogenic Phenotype Involves TRPM7 Modulation by Magnesium. Hypertension, 2010, 56, 453-462.	1.3	192

#	Article	IF	Citations
73	Endothelial Microparticle Formation by Angiotensin II Is Mediated via Ang II Receptor Type I/NADPH Oxidase/ Rho Kinase Pathways Targeted to Lipid Rafts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1898-1907.	1.1	192
74	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	0.8	191
75	Effect of Peroxisome Proliferatorâ€“Activated Receptor-Î± and -Î³ Activators on Vascular Remodeling in Endothelin-Dependent Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 45-51.	1.1	188
76	Oxidative Stress and Hypertension. Circulation Research, 2021, 128, 993-1020.	2.0	188
77	Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury. American Journal of Pathology, 2015, 185, 2309-2323.	1.9	186
78	Transient Receptor Potential Melastatin 7 Ion Channels Regulate Magnesium Homeostasis in Vascular Smooth Muscle Cells. Circulation Research, 2005, 96, 207-215.	2.0	185
79	Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. American Journal of Hypertension, 2002, 15, 78-84.	1.0	183
80	Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II â€“ editorial review. Current Opinion in Nephrology and Hypertension, 2005, 14, 125-131.	1.0	179
81	Animal Models of Hypertension: A Scientific Statement From the American Heart Association. Hypertension, 2019, 73, e87-e120.	1.3	177
82	Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. Journal of Hypertension, 2004, 22, 1141-1149.	0.3	175
83	Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. Journal of the American Society of Hypertension, 2012, 6, 85-99.	2.3	175
84	Oxidative stress and vascular damage in hypertension. Current Hypertension Reports, 2000, 2, 98-105.	1.5	174
85	Role of magnesium in the pathogenesis of hypertension. Molecular Aspects of Medicine, 2003, 24, 107-136.	2.7	174
86	A new look at the reninâ€“angiotensin systemâ€”Focusing on the vascular system. Peptides, 2011, 32, 2141-2150.	1.2	173
87	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
88	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	0.8	170
89	Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 5 (Nox5) Regulation by Angiotensin II and Endothelin-1 Is Mediated via Calcium/Calmodulin-Dependent, Rac-1-Independent Pathways in Human Endothelial Cells. Circulation Research, 2010, 106, 1363-1373.	2.0	167
90	Docosahexaenoic Acid, a Peroxisome Proliferatorâ€“Activated Receptor-Î± Ligand, Induces Apoptosis in Vascular Smooth Muscle Cells by Stimulation of p38 Mitogen-Activated Protein Kinase. Hypertension, 2000, 36, 851-855.	1.3	165

#	Article	IF	Citations
91	Magnesium in clinical medicine. Frontiers in Bioscience - Landmark, 2004, 9, 1278.	3.0	159
92	Vascular Complications of Cancer Chemotherapy. Canadian Journal of Cardiology, 2016, 32, 852-862.	0.8	158
93	Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients. Hypertension, 2008, 51, 432-439.	1.3	156
94	Oxidative stress, Noxs, and hypertension: Experimental evidence and clinical controversies. Annals of Medicine, 2012, 44, S2-S16.	1.5	154
95	p47phox Associates With the Cytoskeleton Through Cortactin in Human Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 512-518.	1.1	153
96	Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1511-1518.	1.1	153
97	Angiotensin II and the vascular phenotype in hypertension. Expert Reviews in Molecular Medicine, 2011, 13, e11.	1.6	152
98	Role of magnesium in hypertension. Archives of Biochemistry and Biophysics, 2007, 458, 33-39.	1.4	151
99	Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 295-307.	1.1	147
100	Role of AT ₂ Receptors in Angiotensin IIâ€“Stimulated Contraction of Small Mesenteric Arteries in Young SHR. Hypertension, 1999, 33, 366-372.	1.3	145
101	Mitogen-Activated Protein/Extracellular Signalâ€“Regulated Kinase Inhibition Attenuates Angiotensin IIâ€“Mediated Signaling and Contraction in Spontaneously Hypertensive Rat Vascular Smooth Muscle Cells. Circulation Research, 1999, 84, 505-515.	2.0	144
102	Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 91-106.	0.6	144
103	Peroxisome Proliferator-Activated Receptor-Î± and Receptor-Î³ Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension. Hypertension, 2003, 42, 737-743.	1.3	144
104	Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Current Opinion in Nephrology and Hypertension, 2009, 18, 122-127.	1.0	142
105	Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of TypeÂ2 diabetes. Clinical Science, 2013, 124, 191-202.	1.8	142
106	Vascular toxicities with VEGF inhibitor therapiesâ€“focus on hypertension and arterial thrombotic events. Journal of the American Society of Hypertension, 2018, 12, 409-425.	2.3	141
107	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC: Cardiovascular Interventions, 2020, 13, 33-45.	1.1	141
108	Physiological and pathophysiological role of magnesium in the cardiovascular system. Journal of Hypertension, 2000, 18, 1177-1191.	0.3	140

#	Article	IF	Citations
109	Systemic microvascular dysfunction in microvascular and vasospastic angina. European Heart Journal, 2018, 39, 4086-4097.	1.0	139
110	Oxidative Stress: A Unifying Paradigm in Hypertension. Canadian Journal of Cardiology, 2020, 36, 659-670.	0.8	138
111	ET A Receptor Blockade Decreases Vascular Superoxide Generation in DOCA-Salt Hypertension. Hypertension, 2003, 42, 811-817.	1.3	134
112	Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascular Pharmacology, 2006, 45, 19-28.	1.0	133
113	Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. Npj Precision Oncology, 2018, 2, 13.	2.3	133
114	Role of endothelin in human hypertension. Canadian Journal of Physiology and Pharmacology, 2003, 81, 533-541.	0.7	132
115	Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1103-H1118.	1.5	132
116	Differential Calcium Regulation by Hydrogen Peroxide and Superoxide in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2004, 44, 200-208.	0.8	127
117	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
118	Angiotensin II-Dependent Chronic Hypertension and Cardiac Hypertrophy Are Unaffected by gp91phox-Containing NADPH Oxidase. Hypertension, 2005, 45, 530-537.	1.3	126
119	Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. Hypertension, 2007, 49, 341-346.	1.3	125
120	Neonatal Oxygen Exposure in Rats Leads to Cardiovascular and Renal Alterations in Adulthood. Hypertension, 2008, 52, 889-895.	1.3	125
121	The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Current Hypertension Reports, 2003, 5, 155-164.	1.5	119
122	Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opinion on Investigational Drugs, 2005, 14, 1019-1031.	1.9	119
123	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. Diabetes, 2017, 66, 2691-2703.	0.3	119
124	Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension, 2020, 76, 1104-1112.	1.3	118
125	Urinary Podocyte Microparticles Identify Prealbuminuric Diabetic Glomerular Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 1401-1407.	3.0	117
126	Role of Extracellular Signal-Regulated Kinases in Angiotensin IIâ€“Stimulated Contraction of Smooth Muscle Cells From Human Resistance Arteries. Circulation, 1999, 99, 392-399.	1.6	114

#	Article	IF	Citations
127	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1130.	3.0	114
128	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II â€“ Therapy. Canadian Journal of Cardiology, 2006, 22, 583-593.	0.8	113
129	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
130	Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome. Canadian Journal of Cardiology, 2014, 30, 534-543.	0.8	110
131	Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. Hypertension, 2019, 74, 1266-1274.	1.3	110
132	Nephropathy and Elevated BP in Mice with Podocyte-Specific NADPH Oxidase 5 Expression. Journal of the American Society of Nephrology: JASN, 2014, 25, 784-797.	3.0	109
133	Downregulation of Nuclear Factor Erythroid 2â€“Related Factor and Associated Antioxidant Genes Contributes to Redox-Sensitive Vascular Dysfunction in Hypertension. Hypertension, 2015, 66, 1240-1250.	1.3	109
134	Loss of Lkb1 in Adult Î² Cells Increases Î² Cell Mass and Enhances Glucose Tolerance in Mice. Cell Metabolism, 2009, 10, 285-295.	7.2	108
135	Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment. Hypertension, 2004, 43, 399-404.	1.3	107
136	Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clinical Science, 2006, 110, 243-253.	1.8	107
137	Cell Signaling of Angiotensin II on Vascular Tone: Novel Mechanisms. Current Hypertension Reports, 2011, 13, 122-128.	1.5	107
138	Ischemia and No Obstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008126.	1.4	107
139	Apocynin, NADPH Oxidase, and Vascular Cells. Hypertension, 2008, 51, 172-174.	1.3	105
140	A New Look at the Eye. Circulation Research, 2009, 104, 9-11.	2.0	104
141	Oxidative Stress, Nox Isoforms and Complications of Diabetesâ€”Potential Targets for Novel Therapies. Journal of Cardiovascular Translational Research, 2012, 5, 509-518.	1.1	104
142	NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. Antioxidants and Redox Signaling, 2014, 20, 2726-2740.	2.5	104
143	Eplerenone Prevents Salt-Induced Vascular Remodeling and Cardiac Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension, 2004, 43, 1252-1257.	1.3	103
144	NOX Isoforms and Reactive Oxygen Species in Vascular Health. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 27-35.	3.4	103

#	Article	IF	Citations
145	Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. Journal of Hypertension, 2020, 38, 1682-1698.	0.3	102
146	Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries. Journal of Hypertension, 1999, 17, 907-916.	0.3	101
147	Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Canadian Journal of Physiology and Pharmacology, 2003, 81, 159-167.	0.7	101
148	Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clinical Science, 2011, 120, 131-141.	1.8	99
149	TRPM7, Magnesium, and Signaling. International Journal of Molecular Sciences, 2019, 20, 1877.	1.8	99
150	Deoxycorticosterone Acetate Plus Salt Induces Overexpression of Vascular Endothelin-1 and Severe Vascular Hypertrophy in Spontaneously Hypertensive Rats. Hypertension, 1995, 25, 769-773.	1.3	99
151	Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1789-H1795.	1.5	98
152	Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. Hypertension, 2016, 67, 535-540.	1.3	98
153	Src Is an Important Mediator of Extracellular Signalâ€“Regulated Kinase 1/2â€“Dependent Growth Signaling by Angiotensin II in Smooth Muscle Cells From Resistance Arteries of Hypertensive Patients. Hypertension, 2001, 38, 56-64.	1.3	97
154	Monotherapy With Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. Hypertension, 2016, 68, 1132-1138.	1.3	97
155	Reactive oxygen species and vascular remodelling in hypertension: Still alive. Canadian Journal of Cardiology, 2006, 22, 947-951.	0.8	96
156	Redox-Sensitive Signaling by Angiotensin II Involves Oxidative Inactivation and Blunted Phosphorylation of Protein Tyrosine Phosphatase SHP-2 in Vascular Smooth Muscle Cells From SHR. Circulation Research, 2008, 103, 149-158.	2.0	96
157	Differential regulation of transient receptor potential melastatin 6 and 7 cation channels by ANG II in vascular smooth muscle cells from spontaneously hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R73-R78.	0.9	95
158	Increased Angiotensin II-Mediated Src Signaling via Epidermal Growth Factor Receptor Transactivation Is Associated With Decreased C-Terminal Src Kinase Activity in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. Hypertension, 2002, 39, 479-485.	1.3	94
159	Antiâ€atherosclerotic effect of the angiotensin 1â€“7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. British Journal of Pharmacology, 2017, 174, 4055-4069.	2.7	94
160	Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. Journal of Hypertension, 2005, 23, 1037-1045.	0.3	92
161	Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H281-H288.	1.5	92
162	Downregulation of Renal TRPM7 and Increased Inflammation and Fibrosis in Aldosterone-Infused Mice. Hypertension, 2008, 51, 915-921.	1.3	91

#	Article	IF	Citations
163	Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. Hypertension, 2015, 66, 149-157.	1.3	91
164	Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK. Antioxidants and Redox Signaling, 2017, 27, 379-397.	2.5	91
165	Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications. Clinical Science, 2017, 131, 1405-1418.	1.8	91
166	Abnormal Adrenal and Vascular Responses to Vasopressin Mediated by a V₁-Vasopressin Receptor in a Patient with Adrenocorticotropin-Independent Macronodular Adrenal Hyperplasia, Cushingâ€™s Syndrome, and Orthostatic Hypotension¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2414-2422.	1.8	90
167	Chemerin Regulates Crosstalk Between Adipocytes and Vascular Cells Through Nox. Hypertension, 2015, 66, 657-666.	1.3	90
168	Endothelin-1 and Angiotensin II Receptors in Cells From Rat Hypertrophied Heart. Circulation Research, 1996, 78, 302-311.	2.0	90
169	c-Srcâ€“Dependent Nongenomic Signaling Responses to Aldosterone Are Increased in Vascular Myocytes From Spontaneously Hypertensive Rats. Hypertension, 2005, 46, 1032-1038.	1.3	89
170	Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. Journal of Hypertension, 2001, 19, 441-449.	0.3	88
171	Involvement of oxidative stress in the profibrotic action of aldosteroneInteraction with the renin-angiotensin system. American Journal of Hypertension, 2004, 17, 597-603.	1.0	88
172	Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. Hypertension, 2006, 48, 271-277.	1.3	88
173	Vascular Nox (NADPH Oxidase) Compartmentalization, Protein Hyperoxidation, and Endoplasmic Reticulum Stress Response in Hypertension. Hypertension, 2018, 72, 235-246.	1.3	88
174	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2007, 23, 539-550.	0.8	87
175	Microparticles Induce Cell Cycle Arrest Through Redoxâ€Sensitive Processes in Endothelial Cells: Implications in Vascular Senescence. Journal of the American Heart Association, 2012, 1, e001842.	1.6	87
176	Proapoptotic and Growth-Inhibitory Role of Angiotensin II Type 2 Receptor in Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats In Vivo. Hypertension, 2000, 35, 1069-1073.	1.3	86
177	Testosterone Induces Vascular Smooth Muscle Cell Migration by NADPH Oxidase and c-Srcâ€“Dependent Pathways. Hypertension, 2012, 59, 1263-1271.	1.3	85
178	Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia, 2017, 60, 927-937.	2.9	85
179	Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clinical Science, 2006, 110, 483-489.	1.8	84
180	Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. Journal of the American Society of Hypertension, 2011, 5, 137-153.	2.3	83

#	Article	IF	Citations
181	Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Molecular and Cellular Endocrinology, 2017, 440, 44-56.	1.6	83
182	p38 MAP Kinase Regulates Vascular Smooth Muscle Cell Collagen Synthesis by Angiotensin II in SHR But Not in WKY. Hypertension, 2001, 37, 574-580.	1.3	81
183	Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension.. Hypertension, 1993, 22, 853-862.	1.3	80
184	Effects of AT 1 and AT 2 Angiotensin Receptor Antagonists in Angiotensin II-Infused Rats. Hypertension, 1998, 31, 487-492.	1.3	78
185	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	0.8	78
186	Chanzyme TRPM7 protects against cardiovascular inflammation and fibrosis. Cardiovascular Research, 2020, 116, 721-735.	1.8	78
187	Effect of Hyperhomocystinemia and Hypertension on Endothelial Function in Methylenetetrahydrofolate Reductaseâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1352-1357.	1.1	76
188	Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition. Hypertension, 2017, 70, 220-226.	1.3	76
189	Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrology Dialysis Transplantation, 2009, 24, 1766-1773.	0.4	75
190	Redox signaling, Nox5 and vascular remodeling in hypertension. Current Opinion in Nephrology and Hypertension, 2015, 24, 425-433.	1.0	75
191	Abnormal Adrenal and Vascular Responses to Vasopressin Mediated by a V1-Vasopressin Receptor in a Patient with Adrenocorticotropin-Independent Macronodular Adrenal Hyperplasia, Cushing's Syndrome, and Orthostatic Hypotension. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2414-2422.	1.8	75
192	Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. American Journal of Hypertension, 2004, 17, 597-603.	1.0	75
193	Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: Effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation. American Journal of Hypertension, 2005, 18, 81-87.	1.0	74
194	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. European Heart Journal, 2021, 42, 2590-2604.	1.0	74
195	VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. Hypertension, 2018, 71, 638-647.	1.3	73
196	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	1.0	73
197	Clinical significance of endothelin in cardiovascular disease. Current Opinion in Cardiology, 1997, 12, 354-367.	0.8	72
198	NOX5: Molecular biology and pathophysiology. Experimental Physiology, 2019, 104, 605-616.	0.9	72

#	Article	IF	Citations
199	Renal Redox-Sensitive Signaling, but Not Blood Pressure, Is Attenuated by Nox1 Knockout in Angiotensin IIâ€“Dependent Chronic Hypertension. Hypertension, 2008, 51, 500-506.	1.3	71
200	Smallâ€Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. Journal of the American Heart Association, 2019, 8, e011104.	1.6	71
201	Recent advances in intracellular signalling in hypertension. Current Opinion in Nephrology and Hypertension, 2003, 12, 165-174.	1.0	70
202	Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. Journal of Hypertension, 2006, 24, 2417-2422.	0.3	70
203	Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistarâ€Kyoto rats and spontaneously hypertensive rats. Journal of Hypertension, 2001, 19, 553-559.	0.3	69
204	Exercise Reverses Metabolic Syndrome in High-Fat Diet-Induced Obese Rats. Medicine and Science in Sports and Exercise, 2011, 43, 398-407.	0.2	68
205	The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. Canadian Journal of Cardiology, 2004, 20, 55-9.	0.8	67
206	Regulation of the novel Mg2+ transporter transient receptor potential melastatin 7 (TRPM7) cation channel by bradykinin in vascular smooth muscle cells. Journal of Hypertension, 2009, 27, 155-166.	0.3	65
207	Transient Receptor Potential Melastatin 7 (TRPM7) Cation Channels, Magnesium and the Vascular System in Hypertension. Circulation Journal, 2011, 75, 237-245.	0.7	65
208	Notch3 signalling and vascular remodelling in pulmonary arterial hypertension. Clinical Science, 2019, 133, 2481-2498.	1.8	65
209	Endothelin, sex and hypertension. Clinical Science, 2008, 114, 85-97.	1.8	64
210	Modulation of vascular smooth muscle cell growth by magnesium?role of mitogen?activated protein kinases. Journal of Cellular Physiology, 2003, 197, 326-335.	2.0	63
211	Dysregulation of Vascular TRPM7 and Annexin-1 Is Associated With Endothelial Dysfunction in Inherited Hypomagnesemia. Hypertension, 2009, 53, 423-429.	1.3	63
212	Adipocyte-Derived Factors Regulate Vascular Smooth Muscle Cells Through Mineralocorticoid and Glucocorticoid Receptors. Hypertension, 2011, 58, 479-488.	1.3	63
213	Vascular Biology of Superoxide-Generating NADPH Oxidase 5â€”Implications in Hypertension and Cardiovascular Disease. Antioxidants and Redox Signaling, 2019, 30, 1027-1040.	2.5	63
214	Nicotinamide Adenine Dinucleotide Phosphate Oxidaseâ€“Mediated Redox Signaling and Vascular Remodeling by 16Î±-Hydroxyestrone in Human Pulmonary Artery Cells. Hypertension, 2016, 68, 796-808.	1.3	62
215	Vascular Nox4. Circulation Research, 2012, 110, 1159-1161.	2.0	61
216	Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nature Communications, 2020, 11, 4222.	5.8	61

#	Article	IF	Citations
217	Multiple actions of angiotensin II in hypertension. Journal of the American College of Cardiology, 2003, 42, 911-913.	1.2	60
218	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	0.8	60
219	Aldosterone, SGK1, and ion channels in the kidney. Clinical Science, 2018, 132, 173-183.	1.8	60
220	Effect of Pressurization on Mechanical Properties of Mesenteric Small Arteries from Spontaneously Hypertensive Rats. Journal of Vascular Research, 1997, 34, 117-125.	0.6	59
221	Personalized medicineâ€”a modern approach for the diagnosis and management of hypertension. Clinical Science, 2017, 131, 2671-2685.	1.8	59
222	Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats. Journal of Hypertension, 2002, 20, 2221-2232.	0.3	57
223	ACE2 the Janus-faced protein â€“ from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clinical Science, 2020, 134, 747-750.	1.8	57
224	Mesenteric vascular smooth muscle cells from spontaneously hypertensive rats display increased calcium responses to angiotensin II but not to endothelin-1. Journal of Hypertension, 1994, 12, 663???674.	0.3	56
225	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I â€“ Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2006, 22, 573-581.	0.8	56
226	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Canadian Journal of Cardiology, 2005, 21, 657-72.	0.8	56
227	Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. Journal of Hypertension, 2002, 20, 1127-1134.	0.3	55
228	Acute ethanol intake induces superoxide anion generation and mitogen-activated protein kinase phosphorylation in rat aorta: A role for angiotensin type 1 receptor. Toxicology and Applied Pharmacology, 2012, 264, 470-478.	1.3	55
229	Chronic Production of Angiotensin IV in the Brain Leads to Hypertension That Is Reversible With an Angiotensin II AT1 Receptor Antagonist. Circulation Research, 2004, 94, 1451-1457.	2.0	54
230	Acute effects of electronic and tobacco cigarettes on vascular and respiratory function in healthy volunteers. Journal of Hypertension, 2019, 37, 154-166.	0.3	54
231	ET A Receptor Mediates Altered Leukocyte-Endothelial Cell Interaction and Adhesion Molecules Expression in DOCAâ€“Salt Rats. Hypertension, 2004, 43, 872-879.	1.3	53
232	Evidence that the vasodilator angiotensin-(1â€“7)-Mas axis plays an important role in erectile function. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2588-H2596.	1.5	53
233	Bradykinin regulates calpain and proinflammatory signaling through TRPM7-sensitive pathways in vascular smooth muscle cells. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 296, R201-R207.	0.9	53
234	Endothelial Microparticle-Derived Reactive Oxygen Species: Role in Endothelial Signaling and Vascular Function. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	1.9	53

#	Article	IF	Citations
235	Drug Treatment of Hypertension: Focus on Vascular Health. Drugs, 2016, 76, 1529-1550.	4.9	53
236	Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation. Journal of Molecular and Cellular Cardiology, 2014, 66, 18-26.	0.9	52
237	Differential ANG II-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H30-H39.	1.5	51
238	Allopurinol Initiation and Change in Blood Pressure in Older Adults With Hypertension. Hypertension, 2014, 64, 1102-1107.	1.3	51
239	Adipocytes, aldosterone and obesity-related hypertension. Journal of Molecular Endocrinology, 2016, 57, F7-F21.	1.1	51
240	Serotonin Signaling Through the 5-HT _{1B} Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1361-1370.	1.1	51
241	Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women. Journal of Hypertension, 2017, 35, 89-97.	0.3	51
242	Interleukin-18 Enhances Vascular Calcification and Osteogenic Differentiation of Vascular Smooth Muscle Cells Through TRPM7 Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1933-1943.	1.1	51
243	Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 2018, 104, 1995-2002.	1.2	51
244	High Fat Diet Attenuates the Anticontractile Activity of Aortic PVAT via a Mechanism Involving AMPK and Reduced Adiponectin Secretion. Frontiers in Physiology, 2018, 9, 51.	1.3	51
245	NADPH Oxidase 5 Is a Proâ€Contractile Nox Isoform and a Point of Crossâ€Talk for Calcium and Redox Signalingâ€Implications in Vascular Function. Journal of the American Heart Association, 2018, 7, .	1.6	51
246	Pseudohyperaldosteronism, Liquorice, and Hypertension. Journal of Clinical Hypertension, 2008, 10, 153-157.	1.0	50
247	Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immuneâ€“inflammatory responses in diabetic Apoe â^'/â^' mice. Diabetologia, 2014, 57, 633-642.	2.9	50
248	Isolation and Differentiation of Murine Macrophages. Methods in Molecular Biology, 2017, 1527, 297-309.	0.4	50
249	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2007, 23, 529-538.	0.8	49
250	Thioredoxin in Vascular Biology: Role in Hypertension. Antioxidants and Redox Signaling, 2008, 10, 1127-1136.	2.5	49
251	Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. American Journal of Hypertension, 1999, 12, 757-765.	1.0	47
252	Candidate Genes That Determine Response to Salt in the Stroke-Prone Spontaneously Hypertensive Rat. Hypertension, 2007, 50, 1134-1141.	1.3	47

#	Article	IF	Citations
253	Role of calcium influx and intracellular calcium stores in angiotensin II-mediated calcium hyper-responsiveness in smooth muscle from spontaneously hypertensive rats. Journal of Hypertension, 1997, 15, 1431-1439.	0.3	46
254	Adipocyte-Specific Mineralocorticoid Receptor Overexpression in Mice Is Associated With Metabolic Syndrome and Vascular Dysfunction: Role of Redox-Sensitive PKG-1 and Rho Kinase. Diabetes, 2016, 65, 2392-2403.	0.3	46
255	Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis. Life Sciences, 2017, 179, 110-119.	2.0	46
256	The Meaning of Mas. Hypertension, 2018, 72, 1072-1075.	1.3	46
257	Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 2021, 135, 71-100.	1.8	46
258	Angiotensin II and Vasopressin Modulate Intracellular Free Magnesium in Vascular Smooth Muscle Cells through Na+-dependent Protein Kinase C Pathways. Journal of Biological Chemistry, 1996, 271, 24353-24358.	1.6	45
259	Endothelin A Receptor Blockade Decreases Expression of Growth Factors and Collagen and Improves Matrix Metalloproteinase-2 Activity in Kidneys from Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 39, 892-900.	0.8	45
260	Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovascular Research, 2011, 91, 720-731.	1.8	45
261	T Cells Are Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the Perivascular Tissue Correlates With Disease Severity. Frontiers in Immunology, 2019, 10, 1979.	2.2	45
262	Activation of the Na+-H+Exchanger Modulates Angiotensin IIâ€“Stimulated Na+-Dependent Mg2+Transport in Vascular Smooth Muscle Cells in Genetic Hypertension. Hypertension, 1999, 34, 442-449.	1.3	44
263	Magnesium transport in hypertension. Pathophysiology, 2007, 14, 205-211.	1.0	44
264	Vascular biology of endothelin. Journal of Cardiovascular Pharmacology, 1998, 32 Suppl 3, S2-13.	0.8	44
265	Follicle-Stimulating Hormone Mediated Calcium Signaling by the Alternatively Spliced Growth Factor Type I Receptor1. Biology of Reproduction, 2000, 62, 1067-1074.	1.2	43
266	Endothelin-1, but not Ang II, Activates MAP Kinases Through c-Srcâ€“Independent Ras-Rafâ€“Dependent Pathways in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1960-1967.	1.1	43
267	Brown Adipose Tissue Regulates Small Artery Function Through NADPH Oxidase 4â€“Derived Hydrogen Peroxide and Redox-Sensitive Protein Kinase G-1Î±. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 455-465.	1.1	43
268	Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart Failure. Journal of Cardiac Failure, 2007, 13, 86-94.	0.7	42
269	Angiotensin-(1â€“7) and Vascular Function. Hypertension, 2018, 71, 68-69.	1.3	42
270	Ca ²⁺ -Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species Production. Hypertension, 2020, 76, 827-838.	1.3	42

#	Article	IF	Citations
271	Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. Hypertension, 2020, 75, 1091-1101.	1.3	42
272	Angiotensin II Regulates Vascular Smooth Muscle Cell pH, Contraction, and Growth Via Tyrosine Kinaseâ€"Dependent Signaling Pathways. Hypertension, 1997, 30, 222-229.	1.3	42
273	Inflammation and Vascular Hypertrophy Induced by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 707-709.	1.1	41
274	Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. Journal of Hypertension, 2007, 25, 1263-1271.	0.3	41
275	Ethanol-induced vasoconstriction is mediated via redox-sensitive cyclo-oxygenase-dependent mechanisms. Clinical Science, 2010, 118, 657-668.	1.8	41
276	Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways. Clinical Science, 2015, 128, 411-423.	1.8	41
277	Effect of magnesium on vascular tone and reactivity in pressurized mesenteric resistance arteries from spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 1997, 75, 293-300.	0.7	40
278	Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. Journal of Hypertension, 2005, 23, 2005-2012.	0.3	40
279	Vascular signaling through cholesterol-rich domains: implications in hypertension. Current Opinion in Nephrology and Hypertension, 2007, 16, 90-104.	1.0	40
280	Î±8 Integrin overexpression in de-differentiated vascular smooth muscle cells attenuates migratory activity and restores the characteristics of the differentiated phenotype. Atherosclerosis, 2007, 195, 303-312.	0.4	40
281	Acute ethanol intake induces mitogen-activated protein kinase activation, platelet-derived growth factor receptor phosphorylation, and oxidative stress in resistance arteries. Journal of Physiology and Biochemistry, 2014, 70, 509-523.	1.3	40
282	Testosterone induces leucocyte migration by NADPH oxidase-driven ROS- and COX2-dependent mechanisms. Clinical Science, 2015, 129, 39-48.	1.8	40
283	Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clinical Science, 2002, 103, 25S-30S.	1.8	39
284	Vasoactive peptides in cardiovascular (patho)physiology. Expert Review of Cardiovascular Therapy, 2007, 5, 531-552.	0.6	39
285	Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 2652-2666.	1.2	39
286	Transient Receptor Potential Melastatin 7 Cation Channel Kinase. Hypertension, 2016, 67, 763-773.	1.3	39
287	Temporal changes in cardiac oxidative stress, inflammation and remodeling induced by exercise in hypertension: Role for local angiotensin II reduction. PLoS ONE, 2017, 12, e0189535.	1.1	39
288	Evolution of a New Class of Antihypertensive Drugs. Hypertension, 2020, 75, 6-15.	1.3	39

#	Article	IF	Citations
289	A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 2022, 28, 1303-1313.	15.2	39
290	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 â€“ blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2008, 24, 455-463.	0.8	38
291	Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension. Journal of Hypertension, 2013, 31, 1043-1048.	0.3	38
292	Patient-Specific iPSC Model of a Genetic Vascular Dementia Syndrome Reveals Failure of Mural Cells to Stabilize Capillary Structures. Stem Cell Reports, 2019, 13, 817-831.	2.3	38
293	Magnesium, calcium, sodium and potassium status in normotensive and hypertensive Johannesburg residents. South African Medical Journal, 1987, 72, 377-81.	0.2	38
294	Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia. Journal of Hypertension, 2011, 29, 1400-1410.	0.3	37
295	Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1192-1200.	1.1	37
296	A Call to Regulate Manufacture and Marketing of Blood Pressure Devices and Cuffs: A Position Statement From the World Hypertension League, International Society of Hypertension and Supporting Hypertension Organizations. Journal of Clinical Hypertension, 2016, 18, 378-380.	1.0	37
297	Cytosolic Calcium Changes Induced by Angiotensin II in Neonatal Rat Atrial and Ventricular Cardiomyocytes Are Mediated via Angiotensin II Subtype 1 Receptors. Hypertension, 1996, 27, 1090-1096.	1.3	37
298	Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of typeÂ2 diabetes mellitus. Clinical Science, 2015, 129, 533-545.	1.8	36
299	Molecular and cellular mechanisms regulating vascular function and structure--implications in the pathogenesis of hypertension. Canadian Journal of Cardiology, 2000, 16, 1137-46.	0.8	36
300	Endothelial Cells Negatively Modulate Reactive Oxygen Species Generation in Vascular Smooth Muscle Cells. Hypertension, 2009, 54, 427-433.	1.3	35
301	Endothelial Gata5 transcription factor regulates blood pressure. Nature Communications, 2015, 6, 8835.	5.8	35
302	Crosstalk Between Vascular Redox and Calcium Signaling in Hypertension Involves TRPM2 (Transient) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.3	35
303	Tyrosine Kinase Signaling Pathways Modulate Angiotensin IIâ€“Induced Calcium ([Ca ²⁺]) Tj ETQq1 1 0.784314 rgBT /Ov	1.3	35
304	Cyclic GMP Inhibits a Pharmacologically Distinct Na+/H+ Exchanger Variant in Cultured Rat Astrocytes via an Extracellular Site of Action. Journal of Neurochemistry, 2002, 68, 1451-1461.	2.1	34
305	Reactive Oxygen Species and Hypertension: A Complex Association. Antioxidants and Redox Signaling, 2008, 10, 1041-1044.	2.5	33
306	Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. Annals of Pharmacotherapy, 2008, 42, 925-932.	0.9	33

#	Article	IF	Citations
307	The Serotonin Transporter Promotes a Pathological Estrogen Metabolic Pathway in Pulmonary Hypertension via Cytochrome P450 1B1. Pulmonary Circulation, 2016, 6, 82-92.	0.8	33
308	Vascular toxicity associated with anti-angiogenic drugs. Clinical Science, 2020, 134, 2503-2520.	1.8	33
309	Insulin attenuates agonist-evoked calcium transients in vascular smooth muscle cells.. Hypertension, 1994, 23, I25-8.	1.3	32
310	Sphingosine-1-Phosphate-Induced Inflammation Involves Receptor Tyrosine Kinase Transactivation in Vascular Cells. Hypertension, 2011, 57, 809-818.	1.3	32
311	Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its Î±-kinase domain. Cellular Signalling, 2013, 25, 2163-2175.	1.7	32
312	Differential renal effects of candesartan at high and ultra-high doses in diabetic miceâ€“potential role of the ACE2/AT2R/Mas axis. Bioscience Reports, 2016, 36, .	1.1	32
313	High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. Journal of Clinical Hypertension, 2016, 18, 714-717.	1.0	32
314	Vascular dysfunction in obese diabetic db/db mice involves the interplay between aldosterone/mineralocorticoid receptor and Rho kinase signaling. Scientific Reports, 2018, 8, 2952.	1.6	32
315	Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 2019, 115, 978-988.	1.8	32
316	ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. Clinical Science, 2021, 135, 387-407.	1.8	32
317	Intracellular Ca 2+ Modulation by Angiotensin II and Endothelin-1 in Cardiomyocytes and Fibroblasts From Hypertrophied Hearts of Spontaneously Hypertensive Rats. Hypertension, 1996, 28, 797-805.	1.3	32
318	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€”care pathways, treatment, and follow-up. Cardiovascular Research, 2022, 118, 1618-1666.	1.8	32
319	An Interaction of Renin-Angiotensin and Kallikrein-Kinin Systems Contributes to Vascular Hypertrophy in Angiotensin II-Induced Hypertension: In Vivo and In Vitro Studies. PLoS ONE, 2014, 9, e111117.	1.1	31
320	Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Frontiers in Physiology, 2015, 6, 269.	1.3	31
321	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 2020, 116, 2185-2196.	1.8	31
322	Vascular Endothelin-1 Expression and Effect of an Endothelin ETA Antagonist on Structure and Function of Small Arteries from Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1998, 31, S309-S312.	0.8	31
323	ER stress and Rho kinase activation underlie the vasculopathy of CADASIL. JCI Insight, 2019, 4, .	2.3	31
324	PARK7/DJ-1 dysregulation by oxidative stress leads to magnesium deficiency: implications in degenerative and chronic diseases. Clinical Science, 2015, 129, 1143-1150.	1.8	30

#	Article	IF	Citations
325	Internal Pudental Artery Dysfunction in Diabetes Mellitus Is Mediated by NOX1-Derived ROS-, Nrf2-, and Rho Kinaseâ€“Dependent Mechanisms. Hypertension, 2016, 68, 1056-1064.	1.3	30
326	Chemerin receptor blockade improves vascular function in diabetic obese mice via redox-sensitive and Akt-dependent pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H1851-H1860.	1.5	30
327	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Science Translational Medicine, 2021, 13, eabg8116.	5.8	30
328	The effect of angiotensin II on platelet intracellular free magnesium and calcium ionic concentrations in essential hypertension. Journal of Hypertension, 1993, 11, 551-558.	0.3	29
329	Attenuated Responses to Angiotensin II in Follitropin Receptor Knockout Mice, a Model of Menopause-Associated Hypertension. Hypertension, 2003, 42, 761-767.	1.3	29
330	Endothelial Cell IL-8, a New Target for Adiponectin. Circulation Research, 2005, 97, 1216-1219.	2.0	29
331	Synergistic vascular protective effects of combined low doses of PPARÎ± and PPARÎ³ activators in angiotensin II-induced hypertension in rats. British Journal of Pharmacology, 2007, 151, 45-53.	2.7	29
332	Hypertension Guidelines. Hypertension, 2016, 67, 688-689.	1.3	29
333	Alterations in intracellular cations and cell membrane ATPase activity in patients with malignant hypertension. Journal of Hypertension, 1995, 13, 867-874.	0.3	28
334	Lipid Rafts Take Center Stage in Endothelial Cell Redox Signaling by Death Receptors. Hypertension, 2006, 47, 16-18.	1.3	28
335	Adventitia-Derived Hydrogen Peroxide Impairs Relaxation of the Rat Carotid Artery via Smooth Muscle Cell p38 Mitogen-Activated Protein Kinase. Antioxidants and Redox Signaling, 2011, 15, 1507-1515.	2.5	28
336	Sex steroids receptors, hypertension, and vascular ageing. Journal of Human Hypertension, 2022, 36, 120-125.	1.0	28
337	Structural Features and Expression of an Alternatively Spliced Growth Factor Type I Receptor for Follitropin Signaling in the Developing Ovary. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 1999, 2, 21-27.	1.7	27
338	Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. Journal of Hypertension, 2002, 20, 899-907.	0.3	27
339	Role of the actin cytoskeleton in angiotensin II signaling in human vascular smooth muscle cells. Canadian Journal of Physiology and Pharmacology, 2005, 83, 91-97.	0.7	27
340	Expression of NAD(P)H Oxidase Subunits and Their Contribution to Cardiovascular Damage in Aldosterone/Salt-Induced Hypertensive Rat. Journal of Korean Medical Science, 2008, 23, 1039.	1.1	27
341	Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Clinical Science, 2014, 127, 57-63.	1.8	27
342	c-Src Inhibition Improves Cardiovascular Function but not Remodeling or Fibrosis in Angiotensin IIâ€“Induced Hypertension. Hypertension, 2016, 68, 1179-1190.	1.3	27

#	Article	IF	Citations
343	Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. Diabetologia, 2019, 62, 1712-1726.	2.9	27
344	High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension. Cardiovascular Research, 2021, 117, 1372-1381.	1.8	27
345	Endothelin Subtype B Receptorâ€“Mediated Calcium and Contractile Responses in Small Arteries of Hypertensive Rats. Hypertension, 1995, 26, 1041-1045.	1.3	27
346	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€”epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	1.8	27
347	Platelet and erythrocyte Mg2+, Ca2+, Na+, K+ and cell membrane adenosine triphosphatase activity in essential hypertension in blacks. Journal of Hypertension, 1992, 10, 571-578.	0.3	26
348	Tissue Targeting of Angiotensin Peptides. Journal of Biological Chemistry, 1997, 272, 12994-12999.	1.6	26
349	Altered angiotensin II-induced small artery contraction during the development of hypertension in spontaneously hypertensive rats. American Journal of Hypertension, 1999, 12, 716-723.	1.0	26
350	Angiotensin II Type I Receptor Modulates Intracellular Free Mg2+ in Renally Derived Cells via Na+-dependent Ca2+-independent Mechanisms. Journal of Biological Chemistry, 2001, 276, 13657-13663.	1.6	26
351	The World Hypertension League and International Society of Hypertension Call on Governments, Nongovernmental Organizations, and the Food Industry to Work to Reduce Dietary Sodium. Journal of Clinical Hypertension, 2014, 16, 99-100.	1.0	26
352	Acetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort. Hypertension, 2015, 65, 1008-1014.	1.3	26
353	Exercise training protects against atherosclerotic risk factors through vascular <scp>NADPH</scp> oxidase, extracellular signalâ€regulated kinase 1/2 and stressâ€activated protein kinase/câ€<scp>J</scp>un <scp>N</scp>â€terminal kinase downregulation in obese rats. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 179-185.	0.9	26
354	Central role of c-Src in NOX5- mediated redox signalling in vascular smooth muscle cells in human hypertension. Cardiovascular Research, 2022, 118, 1359-1373.	1.8	26
355	Intracellular Mg2+, Ca2+, Na2+and K+in platelets and erythrocytes of essential hypertension patients: Relation to blood pressure. Clinical and Experimental Hypertension, 1992, 14, 1189-1209.	0.3	25
356	Vascular Remodeling, Retinal Arteries, and Hypertension. Hypertension, 2007, 50, 603-604.	1.3	25
357	Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. Journal of the American Society of Hypertension, 2007, 1, 189-199.	2.3	25
358	Activation of vascular p38MAPK by mechanical stretch is independent of c-Src and NADPH oxidase: influence of hypertension and angiotensin II. Journal of the American Society of Hypertension, 2012, 6, 169-178.	2.3	25
359	Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress. Life Sciences, 2019, 221, 29-34.	2.0	25
360	Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. Cardiovascular Research, 2020, 116, 1779-1790.	1.8	25

#	Article	IF	Citations
361	Local endothelial DNA repair deficiency causes aging-resembling endothelial-specific dysfunction. Clinical Science, 2020, 134, 727-746.	1.8	25
362	Growth Factors Mediate Intracellular Signaling in Vascular Smooth Muscle Cells Through Protein Kinase Câ€“Linked Pathways. Hypertension, 1997, 30, 1440-1447.	1.3	25
363	The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Canadian Journal of Cardiology, 2002, 18, 604-24.	0.8	25
364	Inhibitors of Na+/Mg2+ exchange activity attenuate the development of hypertension in angiotensin II-induced hypertensive rats. Journal of Hypertension, 2003, 21, 337-344.	0.3	24
365	Ethanol induces vascular relaxation via redox-sensitive and nitric oxide-dependent pathways. Vascular Pharmacology, 2012, 56, 74-83.	1.0	24
366	Mitochondrial Redox Control of Matrix Metalloproteinase Signaling in Resistance Arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 685-688.	1.1	23
367	Potentiation of vascular oxidative stress and nitric oxide-mediated endothelial dysfunction by high-fat diet in a mouse model of estrogen deficiency and hyperandrogenemia. Journal of the American Society of Hypertension, 2009, 3, 295-305.	2.3	23
368	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. Science Translational Medicine, 2021, 13, eabg8117.	5.8	23
369	Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR). Hormone Molecular Biology and Clinical Investigation, 2014, 19, 89-101.	0.3	22
370	Isolation and Differentiation of Human Macrophages. Methods in Molecular Biology, 2017, 1527, 311-320.	0.4	22
371	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 2018, 201, 86-94.	1.2	22
372	Vascular biology of magnesium and its transporters in hypertension. Magnesium Research, 2010, 23, S207-15.	0.4	22
373	Insulin-induced Ca2+ transport is altered in vascular smooth muscle cells of spontaneously hypertensive rats.. Hypertension, 1994, 23, 931-935.	1.3	21
374	Up-regulation of vascular and renal mitogen-activated protein kinases in hypertensive rats is normalized by inhibitors of the Na+/Mg2+ exchanger. Clinical Science, 2003, 105, 235-242.	1.8	21
375	Hypertension Guidelines. Hypertension, 2013, 62, 660-665.	1.3	21
376	Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3. PLoS ONE, 2016, 11, e0162731.	1.1	21
377	The Canadian Hypertension Education Program â€“ a unique Canadian knowledge translation program. Canadian Journal of Cardiology, 2007, 23, 551-555.	0.8	20
378	Downregulated Serum 14, 15-Epoxyeicosatrienoic Acid Is Associated With Abdominal Aortic Calcification in Patients With Primary Aldosteronism. Hypertension, 2018, 71, 592-598.	1.3	20

#	Article	IF	Citations
379	Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose?: Thoughts From the International Society of Hypertension. Hypertension, 2018, 72, 260-262.	1.3	20
380	Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With TesticularÂCancer. JACC: CardioOncology, 2020, 2, 443-455.	1.7	20
381	Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review. Journal of Hypertension, 2021, 39, 223-230.	0.3	20
382	Modulation of Ca2+ transients in neonatal and adult rat cardiomyocytes by angiotensin II and endothelin-1. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 270, H857-H868.	1.5	19
383	Cholesteryl Ester-Transfer Protein Inhibitors Stimulate Aldosterone Biosynthesis in Adipocytes through Nox-Dependent Processes. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 27-34.	1.3	19
384	Hu antigen R is required for NOX-1 but not NOX-4 regulation by inflammatory stimuli in vascular smooth muscle cells. Journal of Hypertension, 2016, 34, 253-265.	0.3	19
385	2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. Journal of Clinical Hypertension, 2016, 18, 1082-1085.	1.0	19
386	Successes of SPRINT, but Still Some Hurdles to Cross. Hypertension, 2016, 67, 268-269.	1.3	19
387	Isolation and Culture of Vascular Smooth Muscle Cells from Small and Large Vessels. Methods in Molecular Biology, 2017, 1527, 349-354.	0.4	19
388	Upregulation of Nrf2 and Decreased Redox Signaling Contribute to Renoprotective Effects of Chemerin Receptor Blockade in Diabetic Mice. International Journal of Molecular Sciences, 2018, 19, 2454.	1.8	19
389	Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. Hypertension, 2020, 76, 1753-1761.	1.3	19
390	Expression of Cell Cycle Proteins in Blood Vessels of Angiotensin IIâ€“Infused Rats. Hypertension, 2001, 37, 604-608.	1.3	18
391	Reactive oxygen species, cell growth, cell cycle progression and vascular remodeling in hypertension. Future Cardiology, 2007, 3, 53-63.	0.5	18
392	Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1481-H1488.	1.5	18
393	PTGER1 Deletion Attenuates Renal Injury in Diabetic Mouse Models. American Journal of Pathology, 2013, 183, 1789-1802.	1.9	18
394	The Effect of Angiotensin-(1-7) in Mouse Unilateral Ureteral Obstruction. American Journal of Pathology, 2015, 185, 729-740.	1.9	18
395	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. CJC Open, 2021, 3, 1257-1272.	0.7	18
396	Lysophosphatidylcholine induces oxidative stress in human endothelial cells via NOX5 activation â€“ implications in atherosclerosis. Clinical Science, 2021, 135, 1845-1858.	1.8	18

#	Article	IF	Citations
397	Interferon-stimulated gene 15 pathway is a novel mediator of endothelial dysfunction and aneurysms development in angiotensin II infused mice through increased oxidative stress. Cardiovascular Research, 2022, 118, 3250-3268.	1.8	18
398	Effect of magnesium on calcium responses to vasopressin in vascular smooth muscle cells of spontaneously hypertensive rats. Journal of Pharmacology and Experimental Therapeutics, 1998, 284, 998-1005.	1.3	18
399	Endothelin-A-Receptor Blockade Improves Renal Function and Doubles the Lifespan of Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2000, 36, S300-S304.	0.8	17
400	Altered Cardiac Endothelin Receptors and Protein Kinase C in Deoxycorticosterone-Salt Hypertensive Rats. Journal of Molecular and Cellular Cardiology, 2000, 32, 665-676.	0.9	17
401	Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension. Current Opinion in Nephrology and Hypertension, 2010, 19, 169-176.	1.0	17
402	Human cord blood CD133+ cells exacerbate ischemic acute kidney injury in mice. Nephrology Dialysis Transplantation, 2012, 27, 3781-3789.	0.4	17
403	Novel Biosensors Reveal a Shift in the Redox Paradigm From Oxidative to Reductive Stress in Heart Disease. Circulation Research, 2016, 119, 969-971.	2.0	17
404	Aldosterone Upregulates Transient Receptor Potential Melastatin 7 (TRPM7). Journal of Biological Chemistry, 2016, 291, 20163-20172.	1.6	17
405	Enhanced Expression of Endothelin-1 Gene May Cause Blood Pressure-Independent Vascular Hypertrophy. Journal of Cardiovascular Pharmacology, 1995, 26, S5-8.	0.8	17
406	Altered cations and muscle membrane ATPase activity in deoxycorticosterone acetate-salt spontaneously hypertensive rats. Journal of Hypertension, 1991, 9, 737-750.	0.3	16
407	Racial Differences in Cell Membrane ATPases and Cellular Cation Content in Urban South African Normotensive and Hypertensive Subjects. American Journal of Hypertension, 1993, 6, 693-700.	1.0	16
408	Moderate Exercise Decreases Inflammation and Oxidative Stress in Hypertension. Hypertension, 2009, 54, 1206-1208.	1.3	16
409	New insights into mechanisms of hypertension. Current Opinion in Nephrology and Hypertension, 2012, 21, 119-121.	1.0	16
410	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. Hypertension, 2016, 68, 266-268.	1.3	16
411	Much Ado about Nâ€¦atrium: modelling tissue sodium as a highly sensitive marker of subclinical and localized oedema. Clinical Science, 2018, 132, 2609-2613.	1.8	16
412	Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study. PLoS ONE, 2014, 9, e97135.	1.1	16
413	Vascular dysfunction and increased cardiovascular risk in hypospadias. European Heart Journal, 2022, 43, 1832-1845.	1.0	16
414	Antiproliferative effect of L-NAME on rat vascular smooth muscle cells. Life Sciences, 2000, 67, 1613-1623.	2.0	15

#	Article	IF	Citations
415	Characterization of myocardium, isolated cardiomyocytes, and blood pressure in WKHA and WKY rats. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H149-H155.	1.5	15
416	Applying the 2005 Canadian Hypertension Education Program recommendations: 3. Lifestyle modifications to prevent and treat hypertension. Cmaj, 2005, 173, 749-751.	0.9	15
417	Role of Î±_{1D}â€adrenoceptors in vascular wall hypertrophy during angiotensin <scp>II</scp>â€induced hypertension. Autonomic and Autacoid Pharmacology, 2015, 35, 17-31.	0.5	15
418	Aldosterone and Ion Channels. Vitamins and Hormones, 2019, 109, 105-131.	0.7	15
419	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. European Journal of Preventive Cardiology, 2020, 27, 682-692.	0.8	15
420	Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol. European Stroke Journal, 2021, 6, 89-101.	2.7	15
421	A four-dimensional computational model of dynamic contrast-enhanced magnetic resonance imaging measurement of subtle blood-brain barrier leakage. NeuroImage, 2021, 230, 117786.	2.1	15
422	Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. Clinical Science, 2020, 134, 2019-2035.	1.8	15
423	Cardiac Type-1 Angiotensin II Receptor Status in Deoxycorticosterone Acetateâ€“Salt Hypertension in Rats. Hypertension, 1997, 30, 1253-1259.	1.3	15
424	Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. Journal of Hypertension, 1994, 12, 1255???1264.	0.3	14
425	Endothelin influences pHi of human platelets through protein kinase C mediated pathways. Thrombosis Research, 1995, 78, 55-65.	0.8	14
426	Inhibitory effects of PPAR-Î³ on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats. Journal of the American Society of Hypertension, 2007, 1, 150-160.	2.3	14
427	Changes in Cardiopulmonary Reserve and Peripheral Arterial Function Concomitantly with Subclinical Inflammation and Oxidative Stress in Patients with Heart Failure with Preserved Ejection Fraction. International Journal of Vascular Medicine, 2014, 2014, 1-8.	0.4	14
428	Vitamin C prevents the endothelial dysfunction induced by acute ethanol intake. Life Sciences, 2015, 141, 99-107.	2.0	14
429	Characterization of constitutive and acid-induced outwardly rectifying chloride currents in immortalized mouse distal tubular cells. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2007-2019.	1.1	14
430	Redox Stress Defines the Small Artery Vasculopathy of Hypertension. Circulation Research, 2017, 120, 1721-1723.	2.0	14
431	Importance of cholesterol-rich microdomains in the regulation of Nox isoforms and redox signaling in human vascular smooth muscle cells. Scientific Reports, 2020, 10, 17818.	1.6	14
432	Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways. Diabetes, 2022, 71, 1282-1298.	0.3	14

#	Article	IF	Citations
433	Activated oxygen metabolites. Journal of Hypertension, 2003, 21, 2235-2238.	0.3	13
434	Signaling of angiotensin II-induced vascular protein synthesis in conduit and resistance arteries in vivo. BMC Cardiovascular Disorders, 2004, 4, 6.	0.7	13
435	Role of angiotensin II type 2 receptor during regression of cardiac hypertrophy in spontaneously hypertensive rats. Journal of the American Society of Hypertension, 2013, 7, 118-127.	2.3	13
436	The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. Journal of Hypertension, 2014, 32, 446-447.	0.3	13
437	Increased blood pressure, vascular inflammation, and endothelial dysfunction in androgen-deficient follitropin receptor knockout male mice. Journal of the American Society of Hypertension, 2007, 1, 353-361.	2.3	12
438	Angiotensin II signalling and calcineurin in cardiac fibroblasts: differential effects of calcineurin inhibitors FK506 and cyclosporine A. Therapeutic Advances in Cardiovascular Disease, 2012, 6, 5-14.	1.0	12
439	Cardiac signaling molecules and plasma biomarkers after cardiac transplantation: Impact of tacrolimus versus cyclosporine. Journal of Heart and Lung Transplantation, 2013, 32, 1222-1232.	0.3	12
440	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 2018, 5, e000924.	0.9	12
441	Cardiotoxicity and myocardial hypoperfusion associated with antiâ€vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 2020, 22, 1276-1277.	2.9	12
442	Peripheral arteriopathy caused by Notch3 gain-of-function mutation involves ER and oxidative stress and blunting of NO/sGC/cGMP pathway. Clinical Science, 2021, 135, 753-773.	1.8	12
443	Exosomes and the cardiovascular system: role in cardiovascular health and disease. Journal of Physiology, 2023, 601, 4923-4936.	1.3	12
444	ENDOTHELIN-1 GENE EXPRESSION AND VASCULAR HYPERTROPHY IN DOCA-SALT HYPERTENSION COMPARED TO SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, S188-S190.	0.9	11
445	SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H1954-H1962.	1.5	11
446	Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. Journal of Hypertension, 2006, 24, 1365-1373.	0.3	11
447	Regulation of Endothelial Nitric Oxide Synthase by Thrombin. Hypertension, 2007, 49, 429-431.	1.3	11
448	Networking Between Systemic Angiotensin II and Cardiac Mineralocorticoid Receptors. Hypertension, 2008, 52, 1016-1018.	1.3	11
449	Altered vascular structure and wave reflection in hypertensive women with low magnesium levels. Journal of the American Society of Hypertension, 2013, 7, 344-352.	2.3	11
450	Management of a Pregnant Woman With Fibromuscular Dysplasia. Hypertension, 2018, 71, 540-547.	1.3	11

#	Article	IF	Citations
451	Hypertension Guidelines: Effect of Blood Pressure Targets. Canadian Journal of Cardiology, 2019, 35, 564-569.	0.8	11
452	Effect of magnesium on vascular tone and reactivity in pressurized mesenteric resistance arteries from spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 1997, 75, 293-300.	0.7	11
453	Clinical significance of endothelin in cardiovascular disease. Current Opinion in Cardiology, 1997, 12, 354-67.	0.8	11
454	Magnesium and hypertension. Current Opinion in Nephrology and Hypertension, 2006, 15, 141-144.	1.0	10
455	Reactive Oxygen Species, Oxidative Stress, and Vascular Biology in Hypertension. , 2007, , 337-347.		10
456	A method for measuring intracellular free magnesium concentration in platelets using flow cytometry. Magnesium Research, 2007, 20, 200-7.	0.4	10
457	Signal transduction in hypertension. Current Opinion in Nephrology and Hypertension, 1993, 2, 5-16.	1.0	9
458	Endothelial receptor subtypes in mesenteric wascular smooth muscle cells of spontaneously hypertensiwe rats. Canadian Journal of Physiology and Pharmacology, 1995, 73, 1262-1273.	0.7	9
459	Differential effects of vasopressin and endothelin-1 on vascular contractile and calcium responses in pressurized small arteries from spontaneously hypertensive rats. Journal of Hypertension, 1996, 14, 983???992.	0.3	9
460	Calcium, Magnesium, and Oxidative Stress in Hyperaldosteronism. Circulation, 2005, 111, 830-831.	1.6	9
461	Off-Target Vascular Effects of Cholesteryl Ester Transfer Protein Inhibitors Involve Redox-Sensitive and Signal Transducer and Activator of Transcription 3-Dependent Pathways. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 415-422.	1.3	9
462	Relations between magnesium, calcium, and plasma renin activity in black and white hypertensive patients. Mineral and Electrolyte Metabolism, 1995, 21, 417-22.	1.1	9
463	Role of Protein Kinase C in the Anti-Aggregatory Effects of Endothelin-1 on Human Platelets. Clinical Science, 1995, 88, 277-283.	1.8	8
464	ETAAND ETBRECEPTORS ON VASCULAR SMOOTH MUSCLE CELLS FROM MESENTERIC VESSELS OF SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, S193-S194.	0.9	8
465	Blunted attenuation of angiotensin II-mediated Ca transients by insulin in cultured unpassaged vascular smooth muscle cells from spontaneously hypertensive rats. American Journal of Hypertension, 1995, 8, 104-112.	1.0	8
466	Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations. Canadian Journal of Cardiology, 2006, 22, 565-571.	0.8	8
467	Linking LOX-1 and Arginase II Through Mitochondria. Circulation Research, 2014, 115, 412-414.	2.0	8
468	Protecting the Heart in Obesity: Role of ACE2 and Its Partners. Diabetes, 2016, 65, 19-21.	0.3	8

#	Article	IF	Citations
469	Title is missing!. American Journal of Hypertension, 2004, 17, 597-603.	1.0	7
470	Relation of serum uric acid to an exaggerated systolic blood pressure response to exercise testing in men with normotension. Journal of Clinical Hypertension, 2018, 20, 551-556.	1.0	7
471	A Compendium on Hypertension. Circulation Research, 2021, 128, 803-807.	2.0	7
472	Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension. Hypertension, 2021, 78, 604-616.	1.3	7
473	Endothelin-1 and Vasopressin Signalling in Blood Vessels of Young SHR in Comparison to Adult SHR.. Hypertension Research, 1996, 19, 121-132.	1.5	7
474	A method for determining the total magnesium, calcium, sodium and potassium contents of human platelets. Mineral and Electrolyte Metabolism, 1991, 17, 173-8.	1.1	7
475	Comparative analysis of hypertensive nephrosclerosis in animal models of hypertension and its relevance to human pathology. Glomerulopathy. PLoS ONE, 2022, 17, e0264136.	1.1	7
476	Signal transduction in hypertension. Current Opinion in Nephrology and Hypertension, 1993, 2, 17-26.	1.0	6
477	Ca2+ and Contractile Responses of Resistance Vessels of WKY Rats and SHR to Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S193-196.	0.8	6
478	Endothelin-A-Receptor Blockade Improves Renal Function and Doubles the Lifespan of Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2000, 36, S300-S304.	0.8	6
479	Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis. Journal of Hypertension, 2005, 23, 329-335.	0.3	6
480	Vascular smooth muscle cells sense calcium: a new paradigm in vascular calcification. Cardiovascular Research, 2008, 81, 237-239.	1.8	6
481	Celebrate World Hypertension Day (<scp>WHD</scp>) on May 17, 2015, and Contribute to Improving Awareness of Hypertension. Journal of Clinical Hypertension, 2015, 17, 317-318.	1.0	6
482	Biomarkers of Oxidative Stress in Human Hypertension. , 2016, , 151-170.		6
483	Hypertension, Diabetes Mellitus, and Excess Cardiovascular Risk. Hypertension, 2017, 70, 882-883.	1.3	6
484	PARP-1 (Poly[ADP-Ribose] Polymerase-1). Hypertension, 2018, 72, 1087-1089.	1.3	6
485	Extracellular Vesicles as Biomarkers and Biovectors in Primary Aldosteronism. Hypertension, 2019, 74, 250-252.	1.3	6
486	Microglia, the Missing Link in the Brain-Gut-Hypertension Axis. Circulation Research, 2019, 124, 671-673.	2.0	6

#	Article	IF	Citations
487	Muscarinic Receptor Type-3 in Hypertension and Cholinergic-Adrenergic Crosstalk: Genetic Insights and Potential for New Antihypertensive Targets. Canadian Journal of Cardiology, 2019, 35, 555-557.	0.8	6
488	Analysis of dynamic texture and spatial spectral descriptors of dynamic contrast-enhanced brain magnetic resonance images for studying small vessel disease. Magnetic Resonance Imaging, 2020, 66, 240-247.	1.0	6
489	Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone. Hypertension, 2020, 76, 962-967.	1.3	6
490	Basal and Angiotensin IIâ€“Induced Cytosolic Free Calcium in Adult Rat Cardiomyocytes and Fibroblasts After Volume Overload. Hypertension, 1995, 26, 1149-1153.	1.3	6
491	Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage. Clinical Science, 2022, 136, 675-694.	1.8	6
492	Magnesium supplementation as an adjuvant to synthetic calcium channel antagonists in the treatment of hypertension. Medical Hypotheses, 1991, 36, 140-141.	0.8	5
493	Mechanosensitive Regulation of Cortactin by p47 phox. Circulation Research, 2013, 112, 1522-1525.	2.0	5
494	Blood Pressure Regulation and Pathology. , 2014, , 257-275.		5
495	The Neuroimmune Axis in the Kidney. Circulation Research, 2015, 117, 487-489.	2.0	5
496	Progenitor Cells, Bone Marrowâ€“Derived Fibrocytes and Endothelial-to-Mesenchymal Transition. Hypertension, 2016, 67, 272-274.	1.3	5
497	Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 2020, 38, 257-265.	0.3	5
498	A New Look At the Mosaic Theory of Hypertension. Canadian Journal of Cardiology, 2020, 36, 591-592.	0.8	5
499	Endothelin-1 Signaling is Altered in Cardiac Cells from Deoxycorticosterone Acetate-Salt Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1998, 31, S179-S181.	0.8	5
500	Acute Ethanol Intake Induces NAD(P)H Oxidase Activation and Rhoa Translocation in Resistance Arteries. Arquivos Brasileiros De Cardiologia, 2016, 107, 427-436.	0.3	5
501	Activated oxygen metabolites: do they really play a role in angiotensin II-regulated vascular tone?. Journal of Hypertension, 2003, 21, 2235-8.	0.3	5
502	Hypertension 2022 Update: Focusing on the Future. Hypertension, 2022, 79, 1559-1562.	1.3	5
503	Tyrosine Kinase Inhibition Attenuates Vasopressin-induced Contraction of Mesenteric Resistance Arteries: Alterations in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 40, 123-132.	0.8	4
504	Impaired vasorelaxation in hypertension: beyond the endothelium. Journal of Hypertension, 2002, 20, 371-373.	0.3	4

#	Article	IF	Citations
505	Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin. European Journal of Applied Physiology, 2011, 111, 1929-1938.	1.2	4
506	Case of Refractory Hypertension Controlled by Repeated Renal Denervation and Celiac Plexus Block. Hypertension, 2017, 69, 978-984.	1.3	4
507	Recommended standards for assessing blood pressure in human research where blood pressure or hypertension is a major focus. Journal of Human Hypertension, 2017, 31, 487-490.	1.0	4
508	Magnesium and Other Biometals in Oxidative Medicine and Redox Biology. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-2.	1.9	4
509	Hypertension and Antiangiogenesis. JACC: CardioOncology, 2019, 1, 37-40.	1.7	4
510	UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1402-1414.	2.4	4
511	Lessons Learned From RAG-1-Deficient Mice in Hypertension. Hypertension, 2020, 75, 935-937.	1.3	4
512	Gut Dysbiosisâ€“Induced Hypertension Is Ameliorated by Intermittent Fasting. Circulation Research, 2021, 128, 1255-1257.	2.0	4
513	Renovascular Hypertension. Hypertension, 2021, 77, 1022-1028.	1.3	4
514	A Framework for Jointly Assessing and Reducing Imaging Artefacts Automatically Using Texture Analysis and Total Variation Optimisation for Improving Perivascular Spaces Quantification in Brain Magnetic Resonance Imaging. Communications in Computer and Information Science, 2020, , 171-183.	0.4	4
515	The relationship between magnesium, calcium, sodium, potassium and blood pressure in South African adult males. Magnesium, 1989, 8, 145-53.	0.3	4
516	Mesenteric vascular smooth muscle cells from spontaneously hypertensive rats display increased calcium responses to angiotensin II but not to endothelin-1. Journal of Hypertension, 1994, 12, 663-73.	0.3	4
517	Treatment of non-insulin-dependent diabetic hypertensive patients with Ca2+ channel blockers is associated with increased platelet sensitivity to insulin*. American Journal of Hypertension, 1995, 8, 1214-1221.	1.0	3
518	Lifestyle Modifications to Prevent and Manage Hypertension for Exercise Physiologists and Fitness Professionals. Applied Physiology, Nutrition, and Metabolism, 2005, 30, 754-761.	1.7	3
519	A Cardiac and a Kidney Transplant Patient Above 6000 Meters in Bolivia. Wilderness and Environmental Medicine, 2009, 20, 99-100.	0.4	3
520	New insights into molecular mechanisms of hypertension. Current Opinion in Nephrology and Hypertension, 2010, 19, 160-162.	1.0	3
521	Mammalian Target of Rapamycin: A Novel Pathway in Vascular Calcification. Canadian Journal of Cardiology, 2014, 30, 482-484.	0.8	3
522	Metabolic Syndrome Sinkholes: What to Do When Occam's Razor Gets Blunted. Canadian Journal of Cardiology, 2015, 31, 601-604.	0.8	3

#	Article	IF	Citations
523	Assessment of Protein Carbonylation and Protein Tyrosine Phosphatase (PTP) Oxidation in Vascular Smooth Muscle Cells (VSMCs) Using Immunoblotting Approaches. Methods in Molecular Biology, 2017, 1614, 31-46.	0.4	3
524	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. Hypertension, 2017, 69, 985-991.	1.3	3
525	Magnesium, Vascular Function, and Hypertension. , 2017, , 353-364.		3
526	Reactive Oxygen Species. , 2019, , 127-136.		3
527	Aldosterone/MR Signaling, Oxidative Stress, and Vascular Dysfunction. , 2019, , .		3
528	Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. Clinical Science, 2021, 135, 2661-2663.	1.8	3
529	Hypertension, alcohol and cations in urban black and coloured South Africans. South African Medical Journal, 1989, 75, 109-13.	0.2	3
530	Rationale and Design for the LOnger-term effects of SARS-CoV-2 INfection on blood Vessels And blood pRessure (LOCHINVAR): an observational phenotyping study. Open Heart, 2022, 9, e002057.	0.9	3
531	Biology of Blood Vessels in Hypertension. Cardiology in Review, 1993, 1, 87-96.	0.6	2
532	Modulation of Ca2+ Transients in Neonatal and Adult Rat Cardiomyocytes by Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S297-299.	0.8	2
533	Pressure-induced expression of vascular neuronal nitric oxide synthase. Journal of Hypertension, 2003, 21, 863-865.	0.3	2
534	Biomarkers in Hypertension. , 2012, , 237-246.		2
535	Reactive Oxygen Species and the Cardiovascular System. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2012, 4, 1-102.	0.3	2
536	Reactive Oxygen Species and Oxidative Stress. , 2012, , 335-338.		2
537	Myocyte growth, repair, and oxidative stress following pediatric heart transplantation. Pediatric Transplantation, 2014, 18, 764-770.	0.5	2
538	Lower is better in hypertension, but how low should blood pressure be targeted?. Journal of the American Society of Hypertension, 2016, 10, 621-622.	2.3	2
539	JS ISH-ECCR-2 ANG-(1â€“7) AND ET-1, A NEW PARTNERSHIP. Journal of Hypertension, 2016, 34, e382.	0.3	2
540	AMPK as a therapeutic target for metabolic disorders: interactions with the reninâ€“angiotensinâ€“aldosterone system in adipocytes. Lancet, The, 2016, 387, S105.	6.3	2

#	Article	IF	Citations
541	A Woman With Treatment-Resistant Hypertension. Hypertension, 2016, 67, 243-250.	1.3	2
542	Assessment of Caveolae/Lipid Rafts in Isolated Cells. Methods in Molecular Biology, 2017, 1527, 251-269.	0.4	2
543	Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction. Hypertension, 2019, 74, 1216-1225.	1.3	2
544	The Î±1D-adrenoreceptor antagonist BMY 7378 reverses cardiac hypertrophy in spontaneously hypertensive rats. Journal of Hypertension, 2020, 38, 1496-1503.	0.3	2
545	CONNed in Pregnancy. Hypertension, 2021, 78, 241-249.	1.3	2
546	Oxidative Stress in Arterial Hypertension: Oxidative Stress and Hypertension. , 2008, , 51-78.		2
547	Vascular progenitor recruitment in critically ill patients with acute kidney injury. Clinical and Investigative Medicine, 2011, 34, 304.	0.3	2
548	Ca2+ and contractile responses of resistance vessels of WKY rats and SHR to endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26 Suppl 3, S193-6.	0.8	2
549	Targeting the ailing endothelium â€“ current concepts and future prospects. Canadian Journal of Cardiology, 2008, 24, 38C-43C.	0.8	1
550	Liquorice alert. British Dental Journal, 2009, 207, 519-519.	0.3	1
551	Persistent Elevation of VEGF and Prostacyclin Following Poor Cardiopulmonary Adaptation to High Altitude. Wilderness and Environmental Medicine, 2009, 20, 97-98.	0.4	1
552	Advancement in hypertension pathogenesis: some new concepts. Current Opinion in Nephrology and Hypertension, 2011, 20, 105-106.	1.0	1
553	Response to European Society of Hypertension and European Society of Cardiology Guidelines and the Muted Enthusiasm for Home Blood Pressure Monitoring. Hypertension, 2014, 63, .	1.3	1
554	Mas Signaling. , 2015, , 169-179.		1
555	Chemiluminescence and the Nox1-Nox2-Nox4 Triple Knockout. Antioxidants and Redox Signaling, 2015, 23, 1246-1247.	2.5	1
556	POA 02-3 SMALL VESSEL DISEASE AND HYPERTENSION â€“ MOLECULAR MECHANISMS AND CLINICAL IMPLICATIONS. Journal of Hypertension, 2016, 34, e33.	0.3	1
557	Case of Primary Aldosteronism With Discordant Hormonal and Computed Tomographic Findings. Hypertension, 2017, 69, 529-535.	1.3	1
558	151â€…Nox5 induces vascular dysfunction and arterial remodelling independently of blood pressure elevation in ang ii-infused nox5-expressing mice. Heart, 2017, 103, A111.1-A111.	1.2	1

#	Article	IF	Citations
559	170â€...Fetuin-a induces nox1-ros-dependent vascular dysfunction partially through toll like receptor 4 activation. Heart, 2017, 103, A119.3-A120.	1.2	1
560	Hypertension Editors Welcome Comments From Regional Hypertension Societies. Hypertension, 2018, 71, 962-962.	1.3	1
561	A9907 Cardiovascular inflammation and fibrosis in TRPM7-kinase deficient mice. Journal of Hypertension, 2018, 36, e58.	0.3	1
562	Microparticles and Exosomes in Cell-Cell Communication. , 2019, , 159-168.		1
563	Case of Episodic and Positional Hypertension. Hypertension, 2020, 76, 614-621.	1.3	1
564	Uncontrolled Hypertension in an Elderly Man on Multiple Antihypertensive Drugs. Hypertension, 2020, 76, 1658-1663.	1.3	1
565	Woman With Polycystic Kidney Disease. Hypertension, 2020, 76, 1332-1338.	1.3	1
566	Resistant Hypertension in a Dialysis Patient. Hypertension, 2020, 76, 278-287.	1.3	1
567	Examining the Relationship between Semiquantitative Methods Analysing Concentration-Time and Enhancement-Time Curves from Dynamic-Contrast Enhanced Magnetic Resonance Imaging and Cerebrovascular Dysfunction in Small Vessel Disease. Journal of Imaging, 2020, 6, 43.	1.7	1
568	Time to fiddle with your unpublished data. Clinical Science, 2021, 135, 101-103.	1.8	1
569	Selective Motion Artefact Reduction via Radiomics and k-space Reconstruction for Improving Perivascular Space Quantification in Brain Magnetic Resonance Imaging. Lecture Notes in Computer Science, 2021, , 151-164.	1.0	1
570	Precision medicine in hypertension. Biochemist, 2016, 38, 35-38.	0.2	1
571	Reactive Oxygen Species, Vascular Disease, and Hypertension. , 2014, , 1123-1154.		1
572	Oxidative Stress, Inflammation, Immune System and Hypertension. , 2019, , 67-74.		1
573	Analysis of Spatial Spectral Features of Dynamic Contrast-Enhanced Brain Magnetic Resonance Images for Studying Small Vessel Disease. Communications in Computer and Information Science, 2020, , 282-293.	0.4	1
574	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 2021, 16, e0260283.	1.1	1
575	Hypertension With Negative Metaiodobenzylguanidine Scintigraphy. Hypertension, 2022, 79, 474-478.	1.3	1
576	[The magnesium global network (MaGNet) to promote research on magnesium in diseases focusing on covid-19]. Magnesium Research, 2021, 34, 90-92.	0.4	1

#	Article	IF	Citations
577	Twenty-four hour ambulatory blood pressure in therapeutically resistant hypertensive patients. Journal of Human Hypertension, 1990, 4, 393-6.	1.0	1
578	An assessment of internship at the teaching hospitals of the University of the Witwatersrand. South African Medical Journal, 1988, 74, 173-7.	0.2	1
579	A Message to the Hypertension Community Regarding the Ukraine Crisis. Hypertension, 2022, , .	1.3	1
580	Measurement of Phospholipase D Activation in Vascular Smooth Muscle Cells. , 2001, 51, 355-362.		0
581	Response to Are the Eutrophic Effects of Angiotensin Receptor Blockers Real?. Hypertension, 2006, 48, .	1.3	0
582	Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
583	Peroxisome Proliferator-Activated Receptors Activator, Rosiglitazone, Improves Vascular Structure and Reduces Lipid Deposition in Atherosclerotic Mthfr Knock-Out Mice. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
584	Disturbed Mg++ transporters in hypertension. Journal of Hypertension, 2008, 26, 2450-2451.	0.3	0
585	63rd Annual Fall Conference and Scientific Session of the American Heart Association Council for High Blood Pressure Research in Association With the Council on the Kidney in Cardiovascular Disease. Hypertension, 2010, 55, 431-434.	1.3	0
586	Changes in Plasma Biomarkers of Inflammation, Oxidative Stress and Thrombosis Following De Novo Cardiac Transplantation: Effects of Immunosuppressive Therapy. Journal of Cardiac Failure, 2010, 16, S32.	0.7	0
587	Renal biomarkers. Journal of Hypertension, 2011, 29, 1700-1702.	0.3	0
588	2010 Annual Fall Conference and Scientific Session of the American Heart Association Council for High Blood Pressure Research in Association With the Council on the Kidney in Cardiovascular Disease. Hypertension, 2011, 57, 521-525.	1.3	0
589	Arterial Hypertension. , 2012, , 1311-1319.		0
590	Combination Antihypertensive Treatment With Aliskiren and Blockers of the Renin-Angiotensin Systemâ€"Reassurance but With a Note of Caution. Canadian Journal of Cardiology, 2013, 29, 521-523.	0.8	0
591	Vascular Function. , 2013, , 45-65.		0
592	Reply to Letter by McIntyre etÂal.. Canadian Journal of Cardiology, 2014, 30, 1733.e3.	0.8	0
593	Clinical Implications. Hypertension, 2014, 63, 197-197.	1.3	0
594	Hypertensive Vasculopathy. , 2014, , 1-28.		0

#	Article	IF	Citations
595	3â€…Angiotensin 1â€“7 regulation of endothelin-1 system in pulmonary hypertension. Heart, 2015, 101, A1.3-A1.	1.2	0
596	Hypertensive Vasculopathy. , 2015, , 1595-1618.		0
597	195â€…Angiotensin-(1-9) Reduces Cardiac Dysfunction in a Model of Angiotensin II-Induced Hypertensive Heart Disease. Heart, 2015, 101, A108.2-A109.	1.2	0
598	Cardiovascular Complications from Cancer Therapy. , 2016, , 185-211.		0
599	OS 15-08 Ang(1â€“7) INFLUENCES ET-1 SIGNALING THROUGH MAS. Journal of Hypertension, 2016, 34, e216.	0.3	0
600	OS 02-01 ROLE OF ALDOSTERONE AND NADPH OXIDASE 1 IN HYPERTENSION-ASSOCIATED VASCULAR AGING. Journal of Hypertension, 2016, 34, e48.	0.3	0
601	[PS 01-14] SYNDECAN-1 IS INVOLVED IN OSTEOPROTEGERIN-INDUCED REACTIVE OXYGEN SPECIES PRODUCTION AND VASCULAR INJURY. Journal of Hypertension, 2016, 34, e100.	0.3	0
602	OS 21-03 EFFECTS OF THE TRPM7 KINASE DOMAIN IN VASCULAR DYSFUNCTION AND CARDIAC FIBROSIS INDUCED BY ALDOSTERONE AND SALT. Journal of Hypertension, 2016, 34, e235-e236.	0.3	0
603	PS 07-14 VASCULAR PROTEIN OXIDATION AND REDOX PROTEOMICS IN HYPERTENSION. Journal of Hypertension, 2016, 34, e287.	0.3	0
604	ISH PRE-2 THE VASCULAR PHENOTYPE IN HYPERTENSION â€“ MOLECULAR MECHANISMS AND CLINICAL IMPLICATIONS. Journal of Hypertension, 2016, 34, e384.	0.3	0
605	Hypertension, diabetes and blood pressure targets: ongoing challenges. Cardiovascular Endocrinology, 2016, 5, 120-121.	0.8	0
606	Acid-Induced Chloride Current in Distal Convoluted Tubule. Biophysical Journal, 2016, 110, 353a.	0.2	0
607	Clinical Scienceâ€“linking basic science to disease mechanisms. Clinical Science, 2017, 131, 511-513.	1.8	0
608	Clinical Science: showcasing the breadth of the journal. Clinical Science, 2017, 131, 1559-1559.	1.8	0
609	224â€…Vascular endothelial growth factor receptor inhibition induces vascular dysfunction via redox-sensitive processes. Heart, 2017, 103, A145.1-A145.	1.2	0
610	159â€…Trpm2 ion channel activation contributes to redox-sensitive vascular dysfunction in hypertension. Heart, 2017, 103, A114-A115.	1.2	0
611	181â€…Nox compartmentalization and protein oxidation in vascular smooth muscle cells â€“ implications in vascular dysfunction in hypertension. Heart, 2017, 103, A125.1-A125.	1.2	0
612	182â€…Syndecan-1 is involved in osteoprotegerin-induced vascular dysfunction. Heart, 2017, 103, A125.2-A125.	1.2	0

#	Article	IF	Citations
613	Resistant Hypertension. Hypertension, 2018, 71, 772-780.	1.3	0
614	Case of Severe Hypertension and Nephrotic Range Proteinuria. Hypertension, 2018, 71, 956-961.	1.3	0
615	A9595 Crosstalk Between Vascular Redox and Calcium Signalling in Hypertension Involves Transient Receptor Potential Melastatin 2 Channel Activation. Journal of Hypertension, 2018, 36, e56.	0.3	0
616	A10274 Interplay between Nox-regulated oxidative stress and ER stress response in experimental hypertension. Journal of Hypertension, 2018, 36, e57-e58.	0.3	0
617	A10215 Altered vascular function in boys with hypospadias- role of reactive oxygen species. Journal of Hypertension, 2018, 36, e196-e197.	0.3	0
618	A10228 Endothelial microparticles from vegf inhibitor (vegfi)-treated cancer patients mediates endothelial cell signaling and et-1 production. Journal of Hypertension, 2018, 36, e58-e59.	0.3	0
619	Dr Giacomo Rossitto interviews Professor Rhian Touyz, on the translational applications of vascular smooth muscle cell biology in cardiovascular disease. Cardiovascular Research, 2018, 114, e43-e43.	1.8	0
620	Cell Biology of Vessels. , 2019, , 23-30.		0
621	Vascular Signaling. , 2019, , 83-91.		0
622	Anatomy and Pharmacology of Vessels. , 2019, , 3-11.		0
623	Response to the letter regarding the hypothesis paper â€œMuch ado about Nâ€¦atrium: modelling tissue sodium as a highly sensitive marker of subclinical and localised oedemaâ€• Clinical Science, 2019, 133, 761-761.	1.8	0
624	50â€…Ischaemia and No Obstructive Coronary Artery Disease (INOCA): prevalence and predictors of coronary vasomotion disorders. , 2019, , .		0
625	Antihypertensive Drugs and Vascular Health. Updates in Hypertension and Cardiovascular Protection, 2019, , 585-605.	0.1	0
626	MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE MARKERS OF ANGIOGENESIS INHIBITOR-INDUCED CARDIOTOXICITY. Journal of the American College of Cardiology, 2020, 75, 1672.	1.2	0
627	Cardiovascular Oncologic Emergencies. , 2021, , 269-290.		0
628	Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan. Hypertension, 2021, 77, 296-307.	1.3	0
629	Reply. JACC: CardioOncology, 2021, 3, 166.	1.7	0
630	Mg 2+ Channels as the Link Between Mg 2+ Deficiency and COMT Downregulation in Salt-Sensitive Hypertension. Hypertension, 2021, 78, 151-154.	1.3	0

#	Article	IF	Citations
631	Magnesium Disorders. , 2004, , 207-211.		0
632	MAGNESIUM NEGATIVELY REGULATES RHOA/RHO KINASE-DEPENDENT SIGNALING AND CONTRACTION IN VASCULAR SMOOTH MUSCLE CELLS-IMPLICATIONS IN HYPERTENSION Rhian Touyz. Journal of Hypertension, 2004, 22, S76.	0.3	0
633	ANGIOTENSIN II-INDUCED HYPERTENSION IS DEPENDENT ON FUNCTIONALLY ACTIVE C-SRCTYROSINE KINASE, BUT NOT FYN. Journal of Hypertension, 2004, 22, S59.	0.3	0
634	ANGIOTENSIN II-INDUCED AT2 STIMULATION NEGATIVELY MODULATES RHO KINASE-DEPENDENT PHOSPHORYLATION OF MYOSIN LIGHT CHAIN IN VASCULAR SMOOTH MUSCLE CELLS AND PROMOTES VASORELAXATION IN SHRSP RESISTANCE ARTERIES. Journal of Hypertension, 2004, 22, S62.	0.3	0
635	INTRACELLULAR CALCIUM MOBILIZATION BY ANGIOTENSIN IV IN PRESENCE OF ANGIOTENSIN II IS AT1-DEPENDEN. Journal of Hypertension, 2004, 22, S172.	0.3	0
636	EPLERENONE PREVENTS CARDIAC AND VASCULAR REMODELING AND IMPROVES RENAL FUNCTION IN SALT-DEPENDENT HYPERTENSION. Journal of Hypertension, 2004, 22, S72.	0.3	0
637	CHARACTERIZATION OF A NEW MURINE TRANSGENIC MODEL OF ENDOTHELIAL CELL HUMAN ENDOTHELIN-1 OVEREXPRESSION.4. Journal of Hypertension, 2004, 22, S30.	0.3	0
638	ENDOTHELIN-1 REGULATES MAP KINASES THROUGH MITOCHONDRIAL-DERIVED REACTIVE OXYGEN SPECIES, WHEREAS ANGIOTENSIN II EFFECTS ARE MEDIATED VIA NADPH OXIDASE-DERIVED SUPEROXIDE IN HUMAN VASCULAR SMOOTH MUSCLE CELLS. Journal of Hypertension, 2004, 22, S112.	0.3	0
639	RESISTANCE ARTERIES IN TYPE 2 DIABETIC PATIENTS UNDER ANTIHYPERTENSIVE TREATMENT SHOW MARKED REMODELING.. Journal of Hypertension, 2004, 22, S129.	0.3	0
640	Angiotensin II and Inflammation. , 2007, , 91-110.		0
641	Reactive Oxygen Species, Oxidative Stress, and Hypertension. , 2010, , 281-315.		0
642	Vascular Biology of Magnesium: Implications in Cardiovascular Disease. , 2013, , 205-220.		0
643	NADPH Oxidase Nox5 Aggravates Renal Injury in Akita Mouse Model of Diabetic Nephropathy. Diabetes, 2018, 67, 505-P.	0.3	0
644	Vascular Biology of Cancer Chemotherapeutic Drugs. , 2019, , 259-268.		0
645	Blood Vessels. , 2019, , 105-116.		0
646	Clinical Science Editorial 2020 â€“ a year gone by and the year ahead. Clinical Science, 2020, 134, 3233-3235.	1.8	0
647	Clinical Science: translating molecular bioscience and experimental research into medical insights. Clinical Science, 2020, 134, 435-437.	1.8	0
648	OP10â€…Skin Na⁺ excess in hypertensive patients: isotonic nature and clinical correlates. , 2020, , .		0

#	Article	IF	Citations
649	Arterial Hypertension. , 2022, , .		0
650	Altered calcium binding to erythrocyte membranes in essential hypertension: relation to magnesium. Journal of Human Hypertension, 1993, 7, 59-64.	1.0	0
651	Rare Disease Leading to Hypertension. Hypertension, 2022, , HYPERTENSIONAHA12218678.	1.3	0
652	Ca2+ and Contractile Responses of Resistance Vessels of WKY Rats and SHR to Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S193-196.	0.8	0
653	Modulation of Ca2+ Transients in Neonatal and Adult Rat Cardiomyocytes by Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S297-299.	0.8	0
654	The vascular phenotype in hypertension. , 2022, , 327-342.		0